Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Uveal Melanoma × tislelizumab × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 31 Colorectal Neoplasms 18 Stomach Neoplasms 14 Carcinoma, Hepatocellular 12 Neoplasm Metastasis 9 Esophageal Squamous Cell Carcinoma 9 Advanced Solid Tumor 9 Squamous Cell Carcinoma of Head and Neck 8 Lung Neoplasms 7 Head and Neck Neoplasms 7 Esophageal Neoplasms 7 Solid Tumor 4 Neoplasms 4 Melanoma 4 Colonic Neoplasms 4 Small Cell Lung Carcinoma 3 Sarcoma 3 Rectal Neoplasms 3 Pancreatic Neoplasms 3 Lymphoma, Follicular 3 Lymphoma 3 Carcinoma, Renal Cell 3 Biliary Tract Neoplasms 3 Adenocarcinoma 3 Uterine Cervical Neoplasms 2 Prostatic Neoplasms 2 Neuroendocrine Tumors 2 Nasopharyngeal Carcinoma 2 Lymphoma, Large B-Cell, Diffuse 2 Locally Advanced Rectal Cancer 2

Interventions

Nivolumab 11 Ipilimumab 10 pembrolizumab 8 Cyclophosphamide 5 tebentafusp 4 Interleukin-2 4 Blood Specimen Collection 4 aflibercept 3 Specimen Handling 3 Radiosurgery 3 Melphalan 3 Magnetic Resonance Spectroscopy 3 relatlimab 2 lenvatinib 2 fludarabine phosphate 2 fludarabine 2 cemiplimab 2 binimetinib 2 Surveys and Questionnaires 2 Carmustine 2 CTLA-4 Antigen 2 Biopsy 2 ulixertinib 1 trametinib 1 tislelizumab 1 sargramostim 1 quisinostat 1 omipalisib 1 olaparib 1 defactinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05542342 2025-05-14

SITISVEAL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡